The Trump administration has bought up the world's supply of COVID-19 drug remdesivir
Health and Human Services Secretary Alex Azar announced Monday an "amazing deal" reached by the Trump administration to purchase nearly all of Gilead's supply of the antiviral drug remdesivir through September. Other countries, which now won't have access to one of two proven treatments for COVID-19 for three months, did not see the deal as so amazing, at least not in the sense Azar meant.
The U.S. "got access to most of the drug supply, so there's nothing for Europe," Dr. Andrew Hill, a research fellow at Liverpool University, told The Guardian. "Imagine this was a vaccine," he added. "That would be a firestorm. But perhaps this is a taste of things to come."
Azar said the U.S. has reserved 100 percent of Gilead's remdesivir production in July and 90 percent in August and September, for a total of about 500,000 doses. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it," Azar said. Each treatment course requires an average of 6.25 vials of remdesivir at a cost of $3,200, HHS said. In other developed countries, Gilead announced, a course of treatment will cost nearly $1,000 less, or $2,340.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The U.S. has the world's worst confirmed COVID-19 outbreak by far — 2.6 million of the world's 10.5 million confirmed cases, 127,000 of 512,000 confirmed deaths — and the disease is not under control. But "the U.S. has taken an 'America first' attitude throughout the global pandemic," The Guardian says, trying to negotiate exclusive rights to a German vaccine and briefly securing first dibs on another vaccine from French pharmaceutical firm Sanofi — before Germany and France, respectively, stepped in.
Remdesivir, developed to fight Ebola (unsuccessfully), has been shown to reduce hospital stays for COVID-19 patients with severe cases. The only other treatment found to be effective is the steroid dexamethasone, which reduced the number of deaths by up to a third in a British study. "There has been no attempt to buy up the world's stocks of dexamethasone because there is no need," The Guardian notes: "The drug is 60 years old, cheap, and easily available everywhere."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The week's best photos
In Pictures Playful goslings, an exploding snowman, and more
By Anahi Valenzuela, The Week US Published
-
What is rock flour and how can it help to fight climate change?
The Explainer Glacier dust to the rescue
By Devika Rao, The Week US Published
-
Crossword: April 19, 2024
The Week's daily crossword puzzle
By The Week Staff Published
-
Post Office's Capture software to be reviewed over 'glitches'
Speed Read Solicitor representing accused postmasters says flaws in the IT system follow 'very similar pattern' to Horizon
By Arion McNicoll, The Week UK Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published
-
Disney and DeSantis reach detente
Speed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
By Peter Weber, The Week US Published
-
Visa and Mastercard agree to lower swipe fees
Speed Read The companies will cap the fees they charge businesses when customers use their credit cards
By Peter Weber, The Week US Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published